

Proposed Analyte Table Change Process Workplace Drug Testing

U.S. Department of Health and Human Services
Substance Abuse and Mental Health Services Administration
Division of Workplace Programs

Mr. Ron Flegel, Division Director

Ms. Lisa Davis, Senior Toxicologist Policy Advisor

DTAB Open Session


March 5, 2024

DTAB Members Discussion



SAMHSA
Substance Abuse and Mental Health
Services Administration

Process for Drug Testing Panel Changes



Review Process: Urine and Oral Fluid Drug Testing Panels

1. Ongoing monitoring for potential panel changes
 - a. Review scientific and medical literature
 - b. Review drug prevalence reports (NFLIS, Quest Drug Testing Information, CDC overdose data)
 - c. Solicit and review information from federal partners (DOT, DoD, DEA), HHS-certified laboratories, MROs, research scientists, manufacturers of collection devices/immunoassay kits

2. Quarterly DTAB meeting: present information on potential panel changes
 - a. FRN 3 weeks prior to meeting
 - i. DTAB meeting date and time
 - ii. Agenda including timeframe and method for providing public comments
 - b. DTAB meeting
 - i. Basis for panel changes
 - ii. Discussion of related costs and benefits

3. Review of public comments

Review Process: Urine and Oral Fluid Drug Testing Panels

4. Next DTAB meeting: present comments and responses
 - a. FRN 3 weeks prior to meeting
 - i. DTAB meeting date and time
 - ii. Agenda
5. DTAB responds to SAMHSA recommendation
6. Federal review process
 - a. Review and respond to comments (may be multiple rounds)
 - b. Give status updates on panel changes at quarterly DTAB meetings
7. Drug Testing Panel Federal Register Notice (annually as needed)
 - a. Basis for any panel changes
 - b. Implementation date for each change

Proposed Testing Panel Changes and Request for Public Comment

- Nov. 17, 2023 Federal Register Notice for Dec. 5, 2023 DTAB meeting
- Public Comment period closed on January 4, 2024

Urine Analyte	Initial Test Cutoff	Confirmation Cutoff
Fentanyl	1 ng/mL	0.5 ng/mL
Norfentanyl	1 ng/mL	0.5 ng/mL

Oral Fluid Analyte	Initial Test Cutoff	Confirmation Cutoff
Fentanyl	1 ng/mL	0.5 ng/mL

Urine and Oral Fluid Analytes
Remove MDMA and MDA from both Urine and Oral Fluid Testing Panels

Analyte Table Decisions

- Feb. 9, 2024 Federal Register Notice for Mar. 5, 2024 DTAB meeting

Urine Initial Test Analyte	Initial Test Cutoff	Confirmatory Test Analytes	Confirmation Cutoff
Fentanyl	1 ng/mL	Fentanyl Norfentanyl	1.0 ng/mL


- Include only Fentanyl (not Norfentanyl) as the sole initial test analyte for urine
- Raise the confirmatory test cutoffs for both Fentanyl and Norfentanyl in urine to 1.0 ng/mL

Oral Fluid Analyte	Initial Test Cutoff	Confirmatory Test Analytes	Confirmation Cutoff
Fentanyl	1 ng/mL	Fentanyl	1.0 ng/mL

- Raise the confirmatory test cutoff for Fentanyl in oral fluid to 1.0 ng/mL
- Remove MDMA and MDA from both urine and oral fluid drug testing panels


Drug Positivity Rates: Blinds Included

Specimens Reported Positive by Drug Category January 2013 – December 2023



Specimens Reported Positive by Drug Category

January 2013 – December 2023



Resources

- December 2023 DTAB Meeting link:

<https://www.samhsa.gov/meetings/dtab-meeting-december-2023>

- March 2024 DTAB Meeting link:

<https://www.samhsa.gov/meetings/dtab-meeting-march-2024>

Thank You
Division of Workplace Programs

Please Visit our Website

<https://www.samhsa.gov/workplace>